-
Second DMD Patient Dies After Treatment with Sarepta Gene Therapy
15 Jun 2025 20:56 GMT
… a patient with Duchenne muscular dystrophy (DMD) following treatment with the marketed … in the ENVISION trial, Sarepta added.
The FDA’s former … unlikely to grow if doctors shy away from Elevidys … research note.
“Previously, our doctors (who were unfazed by …
-
Strengthening Duchenne Care Through Clinical Collaboration and Community Focus: Brenda L. Wong, MD
15 Jun 2025 17:53 GMT
… families affected by Duchenne and Becker muscular dystrophy. The event featured … , health care, and biotechnology, covering current developments in … with industry partners on trial design, and contribute to … Program at UMass Chan Medical School, sat down …
-
[Ad Hoc Announcement Pursuant To Art. 53 LR] Roche Provides Safety Update On Elevidystm Gene Therapy For Duchenne Muscular Dystrophy In Non-Ambulatory Patients
15 Jun 2025 08:49 GMT
… for Duchenne treatment. A robust clinical trial … Sarepta Therapeutics. About Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is … medicines, Roche has grown into the world's largest biotechnology … in Chugai Pharmaceutical, Japan. For …
-
Charity backs brave NI boy's campaign to "end cruel postcode lottery" for drug
15 Jun 2025 15:07 GMT
… plea over "ridiculous" drug costs for son with muscle … the Medicines & Healthcare products Regulatory Agency (MHRA) for the treatment of Duchenne Muscular Dystrophy … opportunity to refer patients to trials in other UK centres if …
-
STAT+: Sarepta reports second patient death after treatment with Duchenne gene therapy
15 Jun 2025 14:40 GMT
… Joseph covers health, medicine, and the biopharma … halting shipments of its Duchenne muscular dystrophy gene therapy for patients … person who received the treatment.
Sarepta disclosed the first … coverage and analysis of the biotech sector — by subscribing …
-
Sarepta reports second case of liver failure death after its gene therapy treatment
15 Jun 2025 07:43 GMT
… form of muscular dystrophy.
The patient was undergoing treatment with Sarepta … S. Food and Drug Administration for Duchenne muscular dystrophy patients aged four … group of experts in Duchenne and liver health … therapy and informed the FDA and global health …
-
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
15 Jun 2025 05:10 GMT
… Duchenne muscular dystrophy. In the U.S., it serves as the confirmatory trial … indicated for the treatment of Duchenne muscular dystrophy (DMD) in … prescription drugs to the FDA. Visit www.fda.gov… development programs, clinical trials, ELEVIDYS, the potential …
-
Questions over cost of muscular dystrophy drug in Belfast Trust
13 Jun 2025 11:18 GMT
… young muscular dystrophy sufferers with a new drug as … already started offering treatment under an early … Duchenne muscular dystrophy in 2016
12 year old Alfie Pentony from Newry has Duchenne Muscular Dystrophy … quot;They take the medicine at home, I would …
-
Parent Project Muscular Dystrophy Announces Children's Hospital of Philadelphia as Certified Duchenne Care Center, Recipient of Inaugural Clinical Research Designation
12 Jun 2025 16:29 GMT
… the fight to end Duchenne muscular dystrophy (Duchenne), is pleased to … to high-quality clinical trials and research opportunities, … centers with active trial programs and research expertise … healthcare providers, cutting edge treatments, and a community …
-
European Commission approves treatment for Duchenne muscular dystrophy
11 Jun 2025 21:53 GMT
… approved for the treatment of Duchenne muscular dystrophy (DMD) in ambulant … double-blind, placebo-controlled trial (NCT02851797). In the … Drug Administration (FDA) in March 2024 for the treatment … approval by the Medicines and Healthcare products …
About
© 1995-2025